Dr Lal Pathlabs Ltd vs Pramodini Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Dr Lal Pathlabs Ltd is ₹ 1845 as of 23 Oct 15:30 . The P/E Ratio of Dr Lal Pathlabs Ltd changed from 77.4 on March 2021 to 43.6 on March 2026 . This represents a CAGR of -9.12% over 6 yearsThe P/E Ratio of Pramodini Medicare Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Dr Lal Pathlabs Ltd changed from ₹ 22565 crore on March 2021 to ₹ 22015 crore on March 2026 . This represents a CAGR of -0.41% over 6 yearsThe Market Cap of Pramodini Medicare Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 years The revenue of Dr Lal Pathlabs Ltd for the Jun '26 is ₹ 829.6 crore as compare to the Mar '26 revenue of ₹ 726.7 crore. This represent the growth of 14.16% The revenue of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Dr Lal Pathlabs Ltd for the Jun '26 is ₹ 279.4 crore as compare to the Mar '26 ebitda of ₹ 210.8 crore. This represent the growth of 32.54% The ebitda of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Dr Lal Pathlabs Ltd changed from ₹ 107.8 crore to ₹ 170.5 crore over 9 quarters. This represents a CAGR of 22.60% The net profit of Pramodini Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The Dividend Payout of Dr Lal Pathlabs Ltd changed from 59.51 % on March 2021 to 67.59 % on March 2026 . This represents a CAGR of 2.14% over 6 yearsThe Dividend Payout of Pramodini Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Dr Lal Pathlabs Ltd

Dr. Lal PathLabs Limited was incorporated as a Private Limited Company with the name Dr. Lal PathLabs Private Limited', on February 14, 1995 at Delhi.
The business of the Partnership Firm, Central Clinical Laboratory was undertaken by the Company.
The Company converted into a Public Limited Company and name of the Company was changed to Dr. Lal PathLabs Limited' vide fresh Certificate of Incorporation granted by the RoC on August 19, 2015. Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres.
Presently, the Company is engaged the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations.

About Pramodini Medicare Ltd

Pramodini Medicare Limited was originally incorporated on September 12, 2000 as 'Pramodini Medicare Private Limited' with the Registrar of Companies, Andhra Pradesh.
Thereafter, the status of the Company changed to public limited Company and the name was changed to 'Pramodini Medicare Limited' vide fresh certificate of incorporation dated November 12, 2025. Company was originally incorporated in the year 2000 with the objective to provide diagnostic services.
The Company provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Diagnostic services include a comprehensive range of offerings: (i) 'Radiology' which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) 'Clinical Laboratory' which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) 'Nuclear Medicine' which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy.

FAQs for the comparison of Dr Lal Pathlabs Ltd and null

Which company has a larger market capitalization, Dr Lal Pathlabs Ltd or Pramodini Medicare Ltd?

Market cap of Dr Lal Pathlabs Ltd is 30,977 Cr while Market cap of Pramodini Medicare Ltd is 239 Cr

What are the key factors driving the stock performance of Dr Lal Pathlabs Ltd and Pramodini Medicare Ltd?

The stock performance of Dr Lal Pathlabs Ltd and Pramodini Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Lal Pathlabs Ltd and Pramodini Medicare Ltd?

As of October 25, 2026, the Dr Lal Pathlabs Ltd stock price is INR ₹1845.55. On the other hand, Pramodini Medicare Ltd stock price is INR ₹108.65.

How do dividend payouts of Dr Lal Pathlabs Ltd and Pramodini Medicare Ltd compare?

To compare the dividend payouts of Dr Lal Pathlabs Ltd and Pramodini Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.